Category: Press Release

Franciscan Health and Ossium Health Perform World's First Organ Donor Bone Marrow Transplant for Non-Malignant Disease

Patient with severe aplastic anemia successfully transplanted, expanding access to a stem cell source long considered optimal for non-malignant conditions

INDIANAPOLIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Franciscan Health and Ossium Health have successfully completed the world's first reported bone marrow transplant to treat a non-malignant disease using bone marrow recovered from a deceased organ donor. The procedure was performed at Franciscan Health using bone marrow supplied by Ossium.

The patient, a 40-year-old woman with a decade-long history of aplastic anemia, received an organ donor bone marrow stem cell transplant on April 18, 2026. Initially diagnosed in 2015, her disease progressed from stable aplastic anemia to severe aplastic anemia despite multiple lines of therapy. Serial bone marrow biopsies demonstrated worsening disease. Because her disease no longer responded to medication, her care team pursued a transplant to replace her failing marrow with healthy blood-forming stem cells. Following a reduced-intensity conditioning regimen, she received a transplant with a cell dose of 6.84 million CD34+ cells/kg from a deceased organ donor.

Six months after transplant, the transplant recipient has achieved durable engraftment and hematologic recovery, meaning the donor marrow has taken hold and restored her blood counts. She is transfusion independent (she no longer needs blood or platelet transfusions) and has achieved full donor chimerism, meaning her blood and immune system are now produced entirely by the donor’s stem cells. To date, she has not experienced graft-versus-host disease (GVHD), a complication in which donor immune cells attack the recipient’s body.

For non-malignant conditions including severe aplastic anemia, sickle cell disease, beta thalassemia, and other inherited or acquired bone marrow failure disorders, bone marrow-derived stem cells are widely regarded as the preferred stem cell source over peripheral blood stem cells (PBSCs). For these transplants, the priority is durable engraftment with the lowest possible risk of chronic GVHD. This differs from transplants for blood cancers, where some donor immune activity helps fight the disease (the graft-versus-leukemia effect). Bone marrow grafts contain fewer T cells (the donor immune cells that drive GVHD) than PBSC grafts and are associated with significantly lower rates of chronic GVHD, making bone marrow the source of choice for non-malignant diseases.

Despite this clinical preference, the majority of unrelated donors from living donor registries ultimately donate PBSCs rather than bone marrow. PBSC collection is less invasive for the donor as it is performed through an outpatient procedure without anesthesia. By contrast, living donor bone marrow aspiration is a surgical procedure performed in an operating room under general or regional anesthesia, and recovery takes longer. Given the choice, many living donors and collection centers favor the less invasive option, leaving bone marrow in comparatively short supply. Organ donor bone marrow supplied by Ossium offers a path to expanding the availability of this preferred graft source without requiring a living donor to undergo a surgical procedure.

“Bone marrow transplantation for severe aplastic anemia has been performed since the 1970s using living related and unrelated donors. To our knowledge, this is the first reported transplant of deceased organ donor bone marrow for severe aplastic anemia,” said Felix Mensah, MD, the treating physician at Franciscan Health. “This case shows why continued innovation in transplant medicine matters, and why we need more donor options, so that every patient with a life-threatening bone marrow failure disorder has access to potentially curative therapy.”

This transplant builds on a milestone Ossium first reached in June 2024, when the first blood cancer patient was treated with the company’s organ donor bone marrow.

“Reaching the first non-malignant transplant is a defining moment," said Kevin Caldwell, CEO, Co-Founder & President of Ossium. "Bone marrow has long been recognized as the optimal graft source for diseases like severe aplastic anemia, sickle cell disease, and beta thalassemia, yet it has remained difficult to access. By recovering and banking bone marrow from organ donors, we can consistently deliver a high cell dose from the preferred graft source to optimize treatment outcomes.”

Ossium plans to support the transplantation of additional patients with both malignant and non-malignant diseases over the course of this year through its HOPE Program, continuing to expand access to deceased donor bone marrow as a graft source for conditions where it offers clear clinical advantages.

About Franciscan Health

The Franciscan Alliance healthcare ministry began in Lafayette, Ind. in 1875. Today, Franciscan Alliance is a large Catholic health care system in the Midwest with 11 hospital campuses, more than 16,000 employees and a number of nationally recognized Centers of Health Care Excellence. Hospitals include Franciscan Health Carmel; Franciscan Health Crawfordsville; Franciscan Health Crown Point; Franciscan Health Dyer; Franciscan Health Indianapolis; Franciscan Health Lafayette; Franciscan Health Michigan City; Franciscan Health Mooresville; Franciscan Health Munster; Franciscan Health Indianapolis Orthopedic Hospital and Franciscan Health Rensselaer.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium's manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Media Contacts

Franciscan Health
Tony Veneziano
317-528-7986
[email protected]

Ossium Health
Jane Griffin
415-513-5535
[email protected]

Ossium Health to Present One-Year Outcomes in Highly Mismatched Organ Donor Bone Marrow Transplants at ASH 2026

SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ossium Health, a bioengineering company that built the world's first bank of organ donor-derived bone marrow, today announced that four abstracts have been selected for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

The featured oral presentation shares Day 180 and Day 365 outcomes from Ossium’s HOPE I Program in patients with acute myeloid leukemia (AML) who received transplants using Ossium's cryopreserved deceased donor bone marrow. Four of the five evaluable patients received grafts matched at only 4 of 8 HLA alleles. All patients engrafted, and none relapsed or experienced graft failure. Three poster presentations cover emergency rescue transplants, the design of the 300-patient PRESERVE II study, and findings from preclinical research that suggest a biological explanation for the rapid engraftment observed clinically.

“Our organ donor-derived bone marrow is consistently enabling successful unrelated donor transplants even with highly mismatched grafts,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. “We look forward to presenting these updated clinical results along with new preclinical data on a biological mechanism that may help explain the remarkable results we’ve seen.”

Oral presentation: one-year HOPE I data in highly mismatched transplants

In the HOPE I Program, four of the five patients who reached Day 180 (80%) received bone marrow matched at only 4 of 8 alleles, while the fifth received a 6 of 8 match. Despite these mismatches, outcomes were consistently positive:

  • Engraftment: 100% of patients achieved neutrophil engraftment, at a median of Day 16 (range: Days 14–20). All patients also achieved platelet engraftment, at a median of Day 21.
  • Chimerism: All five patients showed 100% donor chimerism at Days 30 and 60, meaning their blood was produced entirely by the donor marrow.
  • Durability: No relapses and no graft failures occurred through Day 180 or Day 365.
  • Safety: No serious adverse events were attributed to the Ossium product, and no grade 4 acute graft-versus-host disease (GVHD) occurred. Four patients had grade 1–2 acute GVHD and one had grade 3 . Chronic GVHD in three patients resolved with treatment.
  • Survival: Overall survival was 100% at Day 180. One patient died on Day 282 from an influenza-related infection.

Poster presentations

Emergency rescue transplants. A multicenter case series describes four AML patients at three U.S. transplant centers whose planned living donor became unavailable. In two cases, this happened during conditioning, and in one case on the day of transplant. Each patient instead received a transplant with an HLA-mismatched (4/8 to 6/8) Ossium HPC, Marrow graft. All four successfully engrafted at a median of Day 16, and all remain alive with no relapse, graft failure, or chronic GVHD to date.

PRESERVE II study design. PRESERVE II (NCT07710781) is a 300-patient, multicenter study of patients with hematologic malignancies. It compares Ossium's cryopreserved deceased donor bone marrow with two living donor options: haploidentical related donors and mismatched unrelated donors.

Possible biological mechanism for rapid engraftment with deceased donor marrow. Preclinical research conducted by Ossium and the University of Kansas Medical Center examined the short burst of the signaling protein interleukin-6 (IL-6) that follows brain death. In laboratory studies, a brief, low-dose IL-6 pulse doubled the proportion of the most primitive blood stem cells and helped them survive stress. These findings suggest a possible biological explanation for the rapid engraftment seen in Ossium's clinical studies.

Presentation details

The ASH abstracts are now available at www.hematology.org. Details of Ossium's presentations follow:

Oral Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My!
Title: Cryopreserved whole bone marrow from deceased donors expands the donor pool in HLA-mismatched allogeneic transplantation: Day 180 and Day 365 update from the HOPE I program
Publication Number: 632
Presenter: Jeremy Pantin, MD, Clinical Director, Adult Transplant and Cellular Therapy Program, Sarah Cannon TriStar Centennial Medical Center
Date and Time: December 13, 2026 at 12:00 PM – 1:30 PM CST
Location: Ernest N. Morial Convention Center – Rooms 243-245

Poster Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
Title: Cryopreserved deceased donor bone marrow as an emergency rescue allograft following unexpected donor unavailability: A multicenter case series
Publication Number: 4220
Date and Time: December 13, 2026 at 6:00 PM – 8:00 PM CST
Location: Ernest N. Morial Convention Center – Hall F

Poster Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III
Title: Trial in progress: A multicenter, multiple-arm, open-label study of cryopreserved deceased donor bone marrow and living-donor transplantation (PRESERVE II)
Publication Number: 5974
Date and Time: December 14, 2026 at 6:00 PM – 8:00 PM CST
Location: Ernest N. Morial Convention Center – Hall F

Poster Session: 701. Experimental Transplantation: Basic and Translational: Poster III
Title: A brief pulse of interleukin-6, such as occurs following brain death, enhances fitness of primitive bone marrow hematopoietic stem cells for transplantation
Publication Number: 5855
Date and Time: December 14, 2026 at 6:00 PM – 8:00 PM CST
Location: Ernest N. Morial Convention Center – Hall F

Ossium will also exhibit at Booth #904, where attendees can explore more about Ossium's organ donor-derived bone marrow.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Media Contact
Jane Griffin
Ossium Health
415-513-5535
[email protected]

Ossium Health CEO Kevin Caldwell Wins 2026 Biocom Catalyst Award

SAN FRANCISCO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kevin Caldwell, Ossium Health CEO, Co-Founder & President, has been named a winner of the 2026 Biocom Catalyst Award. Now in its 11th year, the Catalyst Awards honor emerging leaders under 40 who are shaping the future of life science in California and beyond. The awards are presented by Biocom, California’s largest life science membership association. Caldwell is one of 13 awardees in this year’s cohort, which spans AI-designed drugs, personalized cancer vaccines, gene and epigenetic editing, cell therapies, investors, and ecosystem builders.

“Biocom represents the scientists, founders and investors who have made this state a center of life science innovation, so being recognized by this community means a great deal to me and to everyone at Ossium,” said Caldwell. “Joining a class of Catalysts working on gene editing, AI-designed medicines, and aging research signals that banked bone marrow is now part of the conversation about where medicine is headed.”

The award recognizes Caldwell’s work building Ossium into the first bone marrow bank of its kind. For decades, scientists knew that deceased organ donors carry viable hematopoietic stem cells that could be used for bone marrow transplants. But connecting organ procurement organizations with transplant physicians was so complex that the idea was never put into practice. Caldwell co-founded Ossium to close that gap, bringing together organ recovery teams, scientists, federal agencies, and transplant physicians, groups that had never before coordinated at scale.

Under Caldwell’s leadership, Ossium has supplied bone marrow for 29 transplants, some within 48 hours of a physician’s request. Every transplant recipient has engrafted, and no clinically significant adverse events attributable to the product have been reported. Ossium plans to launch commercially in the US in early 2027, with global expansion to follow.

Learn more about all the Catalyst Award winners here.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Media Contact
Jane Griffin
Ossium Health
415-513-5535
[email protected]

Ossium Health Data on On-Demand Organ Donor Bone Marrow Selected as a Top Poster at the 2026 AABB Annual Meeting

Updated data show stem cell viability is preserved through cryopreservation and 100% engraftment in evaluable transplant recipients

SAN FRANCISCO, Oct. 14, 2026 (GLOBE NEWSWIRE) — Ossium Health, a bioengineering company that built the world’s first bank of organ donor-derived bone marrow, announced that its abstract, “On-demand, High-quality Hematopoietic Stem Cells from Deceased Organ Donors,” has been selected as a Top Poster at the 2026 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting in Atlanta. The poster will be featured in the curated Top Posters Tour, “Innovations in Cellular Therapies,” on Sunday, Oct. 18, and displayed in a dedicated Top Poster area throughout the meeting.

AABB is an international, not-for-profit organization dedicated to advancing transfusion medicine and biotherapies, with a professional community in more than 80 countries. Its annual meeting, held Oct. 17–19 this year, brings together physicians, nurses, scientists, researchers, medical technologists and other health care professionals from around the world.

“AABB sets the standards for biobanking and cellular therapy, so having this community recognize our work as a Top Poster means a great deal to our team,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health.

Ossium recovers bone marrow from the vertebrae of screened and consented deceased organ donors, then cryopreserves and banks it as HPC, Marrow so it is ready for allogeneic hematopoietic cell transplantation on demand. To date, 29 patients have been transplanted with Ossium’s bone marrow, some within 48 hours of a physician’s request. The poster updates data previously published in Cytotherapy, with continued accrual following Ossium’s process improvements in July 2024.

Key findings include:

  • Viability: Median post-thaw CD34+ stem cell viability was 86%, with no significant difference between pre-freeze and post-thaw samples.
  • Potency: Post-thaw colony-forming unit assays showed that the cells retain their ability to grow and differentiate.
  • Engraftment: 100% of the 24 patients with engraftment data available at the time of abstract submission have engrafted.
  • Safety: No clinically significant adverse events attributable to the product or excipients were reported.

The authors conclude that deceased donor bone marrow is a feasible and scalable off-the-shelf graft source for allogeneic hematopoietic cell transplantation, and a promising new source of starting material for emerging cell therapies.

“These data show that high-quality bone marrow from deceased organ donors can be recovered, banked and delivered when patients need it, often within 48 hours,” said Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President of Ossium Health. “Patients facing transplant should not have to wait on a donor search, and our bank is built so they don’t have to.”

Presentation details

  • Title: On-demand, High-quality Hematopoietic Stem Cells from Deceased Organ Donors (P-BT-2)
  • Session: Curated Top Posters Tour: Innovations in Cellular Therapies
  • Date and time: Sunday, Oct. 18, 2026, 12:15-1:00 p.m. ET
  • Location: Georgia World Congress Center, Exhibit Halls B2–B3, Biotherapies Pavilion
  • Presenter: Meghann Pierce, DNP, APRN, ANP-C, Medical Science Liaison, Ossium Health
  • Authors: Erik J. Woods, PhD; Kevin Blankenberger; Nicholas Weinstein; Vicki Graves; Hans Nowak; Kelsey Musall; Sagar Munjal, MD; W. Scott Goebel, MD; Brian H. Johnstone, PhD

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50124C00032.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Media Contact:

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

Ossium Health Hosts U.S. Representative Erin Houchin at Indianapolis Production Facility

Congresswoman tours the operational hub of the world’s first organ donor bone marrow bank

INDIANAPOLIS, Sept. 22, 2026 (GLOBE NEWSWIRE) — Ossium Health hosted U.S. Representative Erin Houchin for a tour of its Indianapolis production facility, where the congresswoman observed firsthand the manufacturing operations behind the world’s first bone marrow bank sourced from deceased organ donors.

“Indiana is leading the nation in biotechnology breakthroughs and Ossium Health is at the forefront of that work,” said Rep. Houchin. “I was amazed to see its bone marrow bank firsthand and to learn about the life-saving work they are doing in our state.”

During the visit, the congresswoman toured the production and laboratory space and met with Ossium’s leadership and scientific team to learn about the company’s work to improve treatment outcomes for patients with life-threatening blood and immune diseases.

To date, 29 patients have received transplants using Ossium’s organ donor-derived bone marrow, including four patients in Indiana.

“We were glad to welcome Congresswoman Houchin to our Indianapolis facility,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Every graft we release from this facility goes to a patient in our country who now has a life-saving option they didn’t have before. Having Hoosier leaders see that work up close and understand what it takes to do it matters a great deal.”

Ossium is among Indiana’s most prominent biotech employers, with all of its production, quality, and research operations anchored in Indianapolis. The company has been recognized by Fast Company as one of the Best Workplaces for Innovators and by Forbes as one of America’s Best Startup Employers. It currently has open positions in Indiana for those looking to join its growing team.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Media Contact:
Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

Forbes Names Ossium Health a 2026 Next Billion-Dollar Startup

Recognition highlights the company’s organ donor-derived bone marrow bank and its growing clinical impact

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a bioengineering company that built the world’s first bank of organ donor-derived bone marrow, has been named to the 2026 Forbes Next Billion-Dollar Startups list, Forbes’ annual selection of 20 fast-growing U.S. companies it considers most likely to reach a $1 billion valuation.

Produced by Forbes for the twelfth consecutive year, the list is selected from startups that are venture-backed, based in the United States, and currently valued at less than $1 billion. Of the 275 companies named to the list since its inception, 60% have gone on to become unicorns.

“This recognition reflects the value of the platform we’ve built and the scale of the problem it addresses,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. “Thousands of patients each year never reach transplant because no donor is available in the timeframe their disease allows. Our bank removes this wait from the critical path. As our bone marrow becomes more widely available over the next year, we expect to serve more patients and narrow the donor availability gap.”

Ossium has now treated 28 patients, and in every case the company’s marrow took hold and began producing healthy white blood cells in the recipient, a critical milestone known as neutrophil engraftment.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Media Contact
Jane Griffin
Ossium Health
415-513-5535
[email protected]

Ossium Health Hosts Facility Tour and Reception for Indiana Governor Mike Braun and Healthcare Leaders

Indianapolis Biotech Marks Growing Milestone in the Fight Against Blood Cancer

INDIANAPOLIS–(BUSINESS WIRE)–This week, Ossium Health hosted a facility tour and reception at its Indianapolis production facility, bringing together Indiana state officials and healthcare leaders to celebrate the company’s pioneering work in cell therapy and its contribution to Indiana’s growing biotech economy. Indiana Governor Mike Braun was among the attendees.

Located in Indianapolis, Ossium Health’s nearly 34,000-square-foot facility serves as the operational hub for the company’s groundbreaking organ donor-derived bone marrow banking platform. The facility houses five ISO 7 cleanrooms, a bulk supply warehouse, a dedicated research and development laboratory, and office space for a growing team of production specialists, researchers, and quality personnel.

Attendees toured the facility and met with Ossium’s leadership and scientific team to learn firsthand about the company’s mission to improve treatment outcomes for patients battling life-threatening blood and immune diseases.

Indiana has a long and distinguished history of advancing cell therapy for blood cancers. The science behind the world’s first cord blood transplant was pioneered at the Indiana University (IU) School of Medicine, where IU researchers provided the foundational laboratory work that made the transplant possible. Dr. Erik J. Woods, Ossium’s Chief Science Officer, Co-Founder and Executive Vice President, and Dr. W. Scott Goebel, Ossium’s Medical Director, are themselves products of this tradition. Both trained and conducted research at IU’s Herman B Wells Center for Pediatric Research at Riley Hospital for Children, one of the nation’s preeminent centers for pediatric hematology and oncology.

Dr. Woods developed an optimized cryopreservation method for cord blood stem cells that became widely adopted in the field, and Dr. Goebel has spent his career advancing gene therapy and cellular therapies for hematopoietic diseases at IU School of Medicine. The groundbreaking technology that enabled recovery and banking of bone marrow stem cells from organ donors was developed at Ossium’s Indiana laboratories, built in part on the deep scientific expertise Dr. Woods and Dr. Goebel developed in Indianapolis.

Ossium was founded in 2016 with a revolutionary idea: build a vast bank of bone marrow stem cells sourced from deceased organ donors to provide an off-the-shelf stem cell therapy for patients with blood cancers and immune diseases. Ossium’s bone marrow offers a lifeline to the thousands of patients who cannot find a match through the living donor registry each year, as well as those who need a high-dose, immediately available graft. To date, 23 patients have received transplants using Ossium’s organ donor-derived bone marrow, including two patients in Indiana, a testament to the real and growing impact the company is having on patients across the state and nation.

The event underscores Indiana’s emergence as a national powerhouse in life sciences. According to BioCrossroads, Indiana’s life sciences industry recently surpassed $100 billion in annual economic impact for the first time, and the state has become the nation’s top exporter of life sciences products. Governor Braun has championed a $1 billion growth initiative aimed at making Indiana the premier destination for human therapeutics, biotechnology, and related innovation, with the state’s central region identifying life sciences as a “core growth engine” in its regional development plan.

“Indiana is a national leader in life sciences, and companies like Ossium Health put our state on display,” said Indiana Governor Mike Braun. “Our state is committed to growing high-wage jobs while leading the future of medical innovation and biotech.”

“We are honored to host Governor Braun and our distinguished guests at our Indianapolis facility,” said Kevin Caldwell, Ossium’s CEO, Co-Founder and President. “Indiana has been a tremendous partner in building the infrastructure we need to pursue our mission, and this event is a meaningful recognition of the work our team does every day to save lives.”

Ossium is among Indiana’s most prominent biotech employers, with all of its production, quality, and research operations based in Indianapolis. The company has been recognized by Fast Company as one of the Best Workplaces for Innovators and by Forbes as one of America’s Best Startup Employers, and currently has several open positions in Indiana for those looking to join its growing team.

Ossium is an active participant in Indianapolis’s growing biotech community. Most recently, the company hosted Indy BioBridge’s Q1 Mixer on March 4, 2026, bringing together life sciences professionals from across the region to connect and collaborate at Ossium’s Indianapolis facility. Indy BioBridge is a networking community dedicated to cultivating relationships within Indianapolis’s rapidly expanding life sciences ecosystem.

The event drew broad media attention, with coverage from WISH-TV, CBS, ABC, FOX, News 8, Indianapolis Today, and Hoodline.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X.

Contacts

Media Contact:
Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

Ossium Health to Present New Clinical Data from PRESERVE I Study at the 2026 Tandem Meetings

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a clinical-stage biotechnology company pioneering off-the-shelf bone marrow therapies derived from deceased organ donors, today announced it will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings taking place on February 4-7, 2026 in Salt Lake City, UT.

Ossium will deliver one oral presentation and three poster presentations highlighting clinical experience with its cryopreserved, donor-derived bone marrow platform. The featured oral presentation will showcase first-in-human clinical data from the first four patients treated in the PRESERVE I study, marking an important milestone in the advancement of off-the-shelf bone marrow transplantation. Ossium’s Chief Medical Officer, Dr. Sagar Munjal, will present the study’s encouraging preliminary data, which demonstrate the safety and feasibility of transplanting bone marrow derived from deceased donors. Additional poster presentations underscore key advantages of Ossium’s off-the-shelf bone marrow platform, including its ability to provide immediate graft availability in urgent scenarios when a living donor becomes unavailable, as well as its potential to reduce relapse risk.

Oral Presentation

Title: A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies
Presenter: Sagar Munjal, MD, Chief Medical Officer & Senior Vice President, Ossium Health
Presentation ID: 89
Date and Time: Saturday, Feb 7, 11:30 AM – 11:45 AM MST
Location: Ballroom J

Poster Presentations

Title: First Report of Successful, Lifesaving and Timely Graft Rescue Using an Off-the-Shelf Cryopreserved, Cadaveric Marrow in Myeloablative Transplant Following the Unexpected Unavailability of a Living Matched Unrelated Donor
Poster ID: 160
Date and Time: Thursday, Feb 5, 6:30 PM – 8:00 PM MST
Location: Hall AB

Title: High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update
Poster ID: 280
Date and Time: Thursday, Feb 5, 6:30 PM – 8:00 PM MST
Location: Hall AB

Title: Demonstrating the Feasibility of Refreezing Previously Cryopreserved Bone Marrow Following Reprocessing
Poster ID: 296
Date and Time: Thursday, Feb 5, 6:30 PM – 8:00 PM MST
Location: Hall AB

“These presentations highlight the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. “We look forward to sharing insights from PRESERVE I and related clinical experience with the transplant community at Tandem.”

The company will also exhibit at Booth #106, where attendees can learn more about Ossium’s organ donor-derived bone marrow banking platform and clinical studies.

The Tandem Meetings are jointly hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) and represent one of the premier global forums for advances in hematopoietic cell transplantation and cellular therapy.

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority, under Contract No. 75A50124C00032.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]